BIOMAT Database Logo BIOMAT Database Logo

Considerations when prescribing pharmacotherapy for metabolic associated fatty liver disease. 2022

Lucia Brodosi, and Francesca Marchignoli, and Giulio Marchesini, and Maria Letizia Petroni
Department of Medical and Surgical Sciences, IRCCS-Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.

UI MeSH Term Description Entries
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D012307 Risk Factors An aspect of personal behavior or lifestyle, environmental exposure, inborn or inherited characteristic, which, based on epidemiological evidence, is known to be associated with a health-related condition considered important to prevent. Health Correlates,Risk Factor Scores,Risk Scores,Social Risk Factors,Population at Risk,Populations at Risk,Correlates, Health,Factor, Risk,Factor, Social Risk,Factors, Social Risk,Risk Factor,Risk Factor Score,Risk Factor, Social,Risk Factors, Social,Risk Score,Score, Risk,Score, Risk Factor,Social Risk Factor
D065626 Non-alcoholic Fatty Liver Disease Fatty liver finding without excessive ALCOHOL CONSUMPTION. Fatty Liver, Nonalcoholic,NAFLD,Nonalcoholic Fatty Liver Disease,Nonalcoholic Steatohepatitis,Fatty Livers, Nonalcoholic,Liver, Nonalcoholic Fatty,Livers, Nonalcoholic Fatty,Non alcoholic Fatty Liver Disease,Nonalcoholic Fatty Liver,Nonalcoholic Fatty Livers,Nonalcoholic Steatohepatitides,Steatohepatitides, Nonalcoholic,Steatohepatitis, Nonalcoholic

Related Publications

Lucia Brodosi, and Francesca Marchignoli, and Giulio Marchesini, and Maria Letizia Petroni
Hormone-based pharmacotherapy for metabolic dysfunction-associated fatty liver disease.
April 2024, Medical review (2021),
Lucia Brodosi, and Francesca Marchignoli, and Giulio Marchesini, and Maria Letizia Petroni
What are the main considerations when prescribing pharmacotherapy for Parkinson's disease?
May 2022, Expert opinion on pharmacotherapy,
Lucia Brodosi, and Francesca Marchignoli, and Giulio Marchesini, and Maria Letizia Petroni
Metabolic-associated Fatty Liver Disease.
December 2021, Journal of clinical and translational hepatology,
Lucia Brodosi, and Francesca Marchignoli, and Giulio Marchesini, and Maria Letizia Petroni
What are the key considerations when prescribing pharmacotherapy for sickle cell anemia?
January 2021, Expert opinion on pharmacotherapy,
Lucia Brodosi, and Francesca Marchignoli, and Giulio Marchesini, and Maria Letizia Petroni
Pharmacotherapy for Nonalcoholic Fatty Liver Disease.
August 2015, Seminars in liver disease,
Lucia Brodosi, and Francesca Marchignoli, and Giulio Marchesini, and Maria Letizia Petroni
Lean Metabolic-Associated Fatty Liver Disease.
September 2023, Endocrinology and metabolism clinics of North America,
Lucia Brodosi, and Francesca Marchignoli, and Giulio Marchesini, and Maria Letizia Petroni
Cardiovascular disease in metabolic-associated fatty liver disease.
April 2023, Current opinion in endocrinology, diabetes, and obesity,
Lucia Brodosi, and Francesca Marchignoli, and Giulio Marchesini, and Maria Letizia Petroni
Important considerations when choosing pharmacotherapy for Graves' disease in children.
October 2019, Expert opinion on pharmacotherapy,
Lucia Brodosi, and Francesca Marchignoli, and Giulio Marchesini, and Maria Letizia Petroni
Macrophages in metabolic associated fatty liver disease.
April 2020, World journal of gastroenterology,
Lucia Brodosi, and Francesca Marchignoli, and Giulio Marchesini, and Maria Letizia Petroni
Alcohol and Metabolic-associated Fatty Liver Disease.
October 2021, Journal of clinical and translational hepatology,
Copied contents to your clipboard!